MCD lives on people liking what they eat and eating a lot of it. The Happy Meal is famous.
into the business model comes the new wave biologics for obesity and diabetes. the shots
that cut down the weight and the food addiction. Insurance companies are jumping on
the bandwagon. 1/3 of the people eat half the food. Increasingly, those people are...
CMG has announced a split. Makes sense to make shares more affordable but fractionals are
widely available. CMG may be fundamentally challenged by the underpinnings of the fast food
markets. that is overeating and rising prices. In the meanwhile the anti-obesity and anti-
diabetes trends are pushing hard led by the bological injectable meds from LLY, NVO...
LLY shown on a daily chart has doubled in the past year with the introduction of new FDA
approved drugs into the market. It has but out a series of favorable earnings reports with
optimistic realistic guidance and glowing analysts' forecasts. It has done so without any volume
pumps and just keeps grinding higher. This is because it is in the shadows of big...
My analysis is on the 2H. I am uniquely qualified in my fundamental analysis. This is a one
day until earnings. My thesis is the earnings will stimulate what will be a breakout from
a flat bottom triangle. I will buy one share of stock. I will spend a similar amount on
call options striking $460 expiring August 11th. I see LLY as surging while PFE is a bit...
RSLS, ReShape Lifesciences, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally.
On 11/12/2021 Anthony Vendetti from Maxim Group brokerage Reiterated the Buy Rating for RSLS with a price target of $8.00.
That is more that 5X from the current price.
Looking forward to...
- ReShape leader in weight loss market
- FDA approved Lap-Band manufacturing moved to the US
- eliminated debt overhang
- ReShape Marketplace - digital health solution
June 30, 2021: Cash and cash equivalents and restricted cash were $40.2 million.
ReShape Market Cap only 50.061M
Shares Outstanding 17.20M
On 7/1/2021, Ben Haynor from Alliance Global Partners...
On 6/17/2021 Alliance Global Partners brokerage Boosted the Price Target for RSLS ReShape Lifesciences stock from $12.00 to $18.50!
ReShape Lifesciences is America's premier weight-loss solutions company.
The FDA-approved Lap-Band® program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling...
